KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Derrick Robertson, Enrique Alvarez, Lawrence Steinman, Hans-Peter Hartung, Peiqing Qian, Krzysztof Selmaj, Sibyl Wray, Daniel Wynn, Edward J Fox, Koby Mok, Hari P Miskin, Yihuan Xu, Christopher A Garner, Bruce A C Cree

Front Immunol 17 1771848

PMID42292352
PMCIDPMC13260720
DOI10.3389/fimmu.2026.1771848
发表日期2026-06-15
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:CONSORT/入组流程图;Figure 3:CONSORT/入组流程图;Figure 4:CONSORT/入组流程图;Figure 5:CONSORT/入组流程图;另有 1 张未列出。
摘要

摘要

BACKGROUND: Evidence suggests that treating relapsing multiple sclerosis (RMS) initially with a high-efficacy disease-modifying therapy (DMT) is superior to an escalating approach at reducing disability progression and relapse rate. OBJECTIVES: To evaluate the efficacy of ublituximab versus teriflunomide in participants without prior DMT (treatment-naïve population) and in a subset of treatment-naïve participants with symptom onset ≤ three years (early treatment subpopulation). METHODS: Pooled post hoc analyses of ULTIMATE I/II were conducted at Week 96. RESULTS: The annualized relapse rate was 0.081 for ublituximab (n = 345) versus 0.188 for teriflunomide (n = 377) (p < 0.001) in the treatment-naïve population and 0.130 for ublituximab (n = 139) versus 0.334 for teriflunomide (n = 140) in the early treatment subpopulation (p = 0.004). Twelve-week confirmed disability improvement rates were 10.7% versus 5.3% (p = 0.010) in the treatment-naïve population and 14.4% versus 3.6% (p = 0.002) in the early treatment population (ublituximab vs. teriflunomide). Significant reductions in gadolinium-enhancing T1 lesions and new/enlarging T2 lesions, respectively, occurred for ublituximab versus teriflunomide (treatment naïve: 0.031 vs. 0.791 and 0.390 vs. 4.144; p < 0.001 for both; early treatment: 0.051 vs. 1.030 and 0.508 vs. 6.068; p < 0.001 for both). CONCLUSIONS: Ublituximab was associated with significant treatment benefits at Week 96 in treatment-naïve participants and those receiving treatment within three years of symptom onset. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT03277261 and https://clinicaltrials.gov/study/NCT03277248, identifiers NCT03277261 and NCT03277248.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 ARR at Week 96. a Defined as participants who had not received approved DMT in the five years prior to study enrollment. b Defined as treatment-naïve participants who had their first MS symptom ≤ three years prior to enrollment. mITT population. ARR, annualized relapse rate; CI, confidence interval; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; LS, least squares; mITT, modified intention-to-treat; MS, multiple sclerosis.
非 KM Figure
Figure 2Figure 2 12-week CDI. a Defined as participants who had not received approved DMT in the five years prior to study enrollment. b Defined as treatment-naïve participants who had their first MS symptom ≤ three years prior to enrollment. mITT population. CDI, confirmed disability improvement; CI, confidence interval; DMT, disease-modifying therapy; HR, hazard ratio; mITT, modified intention-to-treat; MS, multiple sclerosis.
非 KM Figure
Figure 3Figure 3 Mean EDSS score change from baseline in the (A) treatment-naïve population a and (B) early treatment subpopulation b . a Defined as participants who had not received approved DMT in the five years prior to study enrollment. b Defined as treatment-naïve participants who had their first MS symptom ≤ three years prior to enrollment. mITT population. DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; mITT, modified intention-to-treat; MS, multiple sclerosis.
非 KM Figure
Figure 4Figure 4 (A) Gd+ T1 lesions and (B) new/enlarging T2 lesions. a Defined as participants who had not received approved DMT in the five years prior to study enrollment. b Defined as treatment-naïve participants who had their first MS symptom ≤ three years prior to enrollment. mITT-MRI population. CI, confidence interval; DMT, disease-modifying therapy; Gd+, gadolinium-enhancing; LS, least squares; mITT, modified intention-to-treat; MRI, magnetic resonance imaging; MS, multiple sclerosis.
非 KM Figure
Figure 5Figure 5 LS mean change from baseline in MSFC score. a Defined as participants who had not received approved DMT in the five years prior to study enrollment. b Defined as treatment-naïve participants who had their first MS symptom ≤ three years prior to enrollment. mITT population. CI, confidence interval; DMT, disease-modifying therapy; LS, least squares; mITT, modified intention-to-treat; MS, multiple sclerosis; MSFC, Multiple Sclerosis Functional Composite.
非 KM Figure
Figure 6Figure 6 NEDA-3 at Weeks 24–96 (re-baselined). a Defined as participants who had not received approved DMT in the five years prior to study enrollment. b Defined as treatment-naïve participants who had their first MS symptom ≤ three years prior to enrollment. mITT population. Pooled post hoc analysis. NEDA-3 was defined as no confirmed relapses, no Gd+ T1 lesions, no new/enlarging T2 lesions, and no disability progression confirmed for at least 12 weeks. CI, confidence interval; DMT, disease-modifying therapy; Gd+, gadolinium-enhancing; mITT, modified intention-to-treat; MRI, magnetic resonance imaging; MS, multiple sclerosis; NEDA-3, three-parameter no evidence of disease activity.
非 KM Figure